Literature DB >> 22135979

[Hypertriglyceridemia: therapeutic strategy].

Christine Cugnet-Anceau1, Myriam Moret, Philippe Moulin.   

Abstract

Causes of hypertriglyceridemia (HTG) vary according to their severity and to their character pure or mixed. Environmental factors including caloric intake excess, fructose overload, alcohol consumption, metabolic syndrom, diabetes, and drug exposure are mostly involved in pure, mild HTG. In contrast, the main etiology of mixed HTG (combined dyslipidemia) is familial combined hyperlipidemia which is commonly associated with metabolic syndrome. Major HTG (> 10 g/L) results mostly from genetic disorder in lipid metabolism with a variable contribution of environmental factors. The complications of HTG are an increased risk of acute pancreatitis (TG > 10 g/L) and a controversial atherogenic risk. Lifestyle modification is the treatment cornerstone. Nevertheless, statins are generally considered as the first drug if a medication is necessary for mixed hyperlipidemia. Fibrates may be used in combination with statin for patient with high atherogenic risk and simultaneous residual hypertriglycéridémie and low HDLc or in high risk patient with severe pure hypertriglyceridemia.

Entities:  

Mesh:

Year:  2011        PMID: 22135979

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  2 in total

1.  From moderately severe to severe hypertriglyceridemia induced acute pancreatitis: circulating miRNAs play role as potential biomarkers.

Authors:  Fangmei An; Qiang Zhan; Min Xia; Lisha Jiang; Guoming Lu; Mindan Huang; Jizhong Guo; Side Liu
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

2.  Lipid levels and new-onset diabetes in a hypertensive population: the China Stroke Primary Prevention Trial.

Authors:  Leliang Li; Ping Li; Juan Yang; Xiao Huang; Huihui Bao; Chunyan Zhang; Yun Song; Min Zhao; Meng Ji; Yi Wang; Geng Qian; Genfu Tang; Shanqun Jiang; Qiang Dong; Yan Zhang; Jianping Li; Xiping Xu; Binyan Wang; Yong Huo; Xiaoshu Cheng
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.